Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Work In Process (2017 - 2025)

Neurocrine Biosciences' Work In Process history spans 9 years, with the latest figure at $13.8 million for Q1 2025.

  • For Q1 2025, Work In Process rose 15.0% year-over-year to $13.8 million; the TTM value through Mar 2025 reached $13.8 million, up 15.0%, while the annual FY2024 figure was $10.9 million, 12.37% up from the prior year.
  • Work In Process reached $13.8 million in Q1 2025 per NBIX's latest filing, up from $10.9 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $13.8 million in Q1 2025 to a low of $3.6 million in Q4 2021.
  • Average Work In Process over 5 years is $9.8 million, with a median of $10.8 million recorded in 2024.
  • Peak YoY movement for Work In Process: skyrocketed 73.21% in 2023, then increased 12.37% in 2024.
  • A 5-year view of Work In Process shows it stood at $3.6 million in 2021, then skyrocketed by 55.56% to $5.6 million in 2022, then soared by 73.21% to $9.7 million in 2023, then rose by 12.37% to $10.9 million in 2024, then rose by 26.61% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Work In Process are $13.8 million (Q1 2025), $10.9 million (Q4 2024), and $10.6 million (Q3 2024).